Humacyte Valuation
| HUMA Stock | USD 1.31 0.04 3.15% |
Today, the firm appears to be undervalued. Humacyte retains a regular Real Value of $2.95 per share. The prevalent price of the firm is $1.31. Our model calculates the value of Humacyte from evaluating the firm fundamentals such as Return On Asset of -0.63, shares outstanding of 187.27 M, and Return On Equity of -2.5 as well as inspecting its technical indicators and probability of bankruptcy. Key fundamental drivers impacting Humacyte's valuation include:
Price Book 70.1666 | Enterprise Value | Enterprise Value Ebitda 4.3389 | Price Sales 156.1588 | Forward PE 35.8423 |
Undervalued
Today
Please note that Humacyte's price fluctuation is dangerous at this time. Calculation of the real value of Humacyte is based on 3 months time horizon. Increasing Humacyte's time horizon generally increases the accuracy of value calculation and significantly improves the predictive power of the methodology used.
Since Humacyte is currently traded on the exchange, buyers and sellers on that exchange determine the market value of Humacyte Stock. However, Humacyte's intrinsic value may or may not be the same as its current market price, in which case there is an opportunity to profit from the mispricing, assuming the market price will eventually merge with its intrinsic value. | Historical | Market 1.31 | Real 2.95 | Target 7.86 | Hype 1.31 | Naive 1.27 |
The real value of Humacyte Stock, also known as its intrinsic value, is the underlying worth of Humacyte Company, which is reflected in its stock price. It is based on Humacyte's financial performance, growth prospects, management team, or industry conditions. The intrinsic value of Humacyte's stock can be calculated using various methods such as discounted cash flow analysis, price-to-earnings ratio, or price-to-book ratio. That value may differ from its current market price, which is determined by supply and demand factors such as investor sentiment, market trends, or news.
Estimating the potential upside or downside of Humacyte helps investors to forecast how Humacyte stock's addition to their portfolios will impact the overall performance. We also use other valuation drivers to help us estimate the true value of Humacyte more accurately as focusing exclusively on Humacyte's fundamentals will not take into account other important factors: Traditionally, analysts and sophisticated investors use multiple methods for valuing a cash-flow-generating entity or its stock. For example, some money managers use Humacyte's intrinsic value based on its ongoing forecasts of Humacyte's financial statements. In contrast, other private, professional wealth advisors use a multiplier approach by looking to relative value analysis against Humacyte's closest peers. If more than one evaluation category is relevant for Humacyte we suggest using both methods to arrive at a better estimate.
Humacyte Cash |
|
Humacyte Total Value Analysis
Humacyte is currently expected to have valuation of 248.17 M with market capitalization of 245.33 M, debt of 16.54 M, and cash on hands of 189.04 M. Please note that valuation may be misleading and is a subject to auditing or accounting errors. We encourage investors to vigilantly validate all of the Humacyte fundamentals before making equity appraisal based on enterprise value of the company| Takeover Price | Market Cap | Debt Obligations | Cash |
248.17 M | 245.33 M | 16.54 M | 189.04 M |
Humacyte Asset Utilization
One of the ways to look at asset utilization of Humacyte is to check how much profit was generated for every dollar of assets it reports. Humacyte retains a negative application of resources of -0.63 (percent), losing $0.006344 for each dollar of resources held by the firm. Inadequate asset utilization attests that the company is being less effective with each dollar of resources it retains. Simply put, asset utilization of Humacyte shows how discouraging it operates for each dollar spent on its resources.Humacyte Ownership Allocation
Humacyte has a total of 187.27 Million outstanding shares. Humacyte retains significant amount of outstanding shares owned by insiders and institutional investors . On June 13, 2024, Senator Tommy Tuberville of US Senate acquired under $15k worth of Humacyte's common stock.Humacyte Profitability Analysis
Net Loss for the year was (148.7 M) with loss before overhead, payroll, taxes, and interest of (73.8 M).Please note that valuation analysis is one of the essential comprehensive assessments in business. It evaluates Humacyte's worth, which you can determine by considering its current assets, liabilities and future cash flows. The investors' valuation analysis is an important metric that will give you a perspective on different companies. It helps you know the worth of the potential investment in Humacyte and how it compares across the competition.
About Humacyte Valuation
The stock valuation mechanism determines Humacyte's current worth on a weekly basis. Our valuation model uses a comparative analysis of Humacyte. We calculate exposure to Humacyte's market risk, different technical and fundamental indicators, and relevant financial multiples and ratios and then compare them to those of Humacyte's related companies.| Last Reported | Projected for Next Year | ||
| Gross Profit | -7.2 M | -7.5 M | |
| Pretax Profit Margin | (6.88) | (7.22) | |
| Operating Profit Margin | (62.15) | (65.26) | |
| Net Loss | (6.88) | (7.22) | |
| Gross Profit Margin | (4.92) | (5.16) |
Humacyte Growth Indicators
Growth stocks usually refer to those companies expected to grow sales and earnings faster than the market average. Growth stocks typically don't pay dividends, often look expensive, and usually trading at a high P/E ratio. Nevertheless, such valuations could be relatively cheap if the company continues to grow, which will drive the share price up. However, since most investors are paying a high price for a growth stock, based on expectations, if those expectations are not fully realized, growth stocks can see dramatic declines.
| Common Stock Shares Outstanding | 118.5 M | |
| Forward Price Earnings | 35.8423 |
Humacyte Current Valuation Indicators
Valuation refers to the process of determining the present value of Humacyte and all of its assets. It can be calculated using a number of techniques. As many analysts who try to value Humacyte we look at many different elements of the entity such as Humacyte's management, its prospective future earnings, the current market value of the company's assets, as well as its capital structure formation.
Valuations are an essential part of business, for companies themselves, but also for investors. For companies, such as Humacyte, valuations can help measure their progress and success and can help them track their performance in the market compared to others. In addition, investors can use Humacyte's valuations to help determine the worth of potential investments. They can do this by using data and information made public by a company. Regardless of who the valuation is for, it essentially describes Humacyte's worth.Complementary Tools for Humacyte Stock analysis
When running Humacyte's price analysis, check to measure Humacyte's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Humacyte is operating at the current time. Most of Humacyte's value examination focuses on studying past and present price action to predict the probability of Humacyte's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Humacyte's price. Additionally, you may evaluate how the addition of Humacyte to your portfolios can decrease your overall portfolio volatility.
| Portfolio Rebalancing Analyze risk-adjusted returns against different time horizons to find asset-allocation targets | |
| Financial Widgets Easily integrated Macroaxis content with over 30 different plug-and-play financial widgets | |
| Aroon Oscillator Analyze current equity momentum using Aroon Oscillator and other momentum ratios | |
| Stock Tickers Use high-impact, comprehensive, and customizable stock tickers that can be easily integrated to any websites | |
| Analyst Advice Analyst recommendations and target price estimates broken down by several categories | |
| CEOs Directory Screen CEOs from public companies around the world | |
| Investing Opportunities Build portfolios using our predefined set of ideas and optimize them against your investing preferences | |
| Instant Ratings Determine any equity ratings based on digital recommendations. Macroaxis instant equity ratings are based on combination of fundamental analysis and risk-adjusted market performance | |
| Idea Analyzer Analyze all characteristics, volatility and risk-adjusted return of Macroaxis ideas |